ClinicalTrials.gg
RecruitingNCT07087626COPDUpdated Jun 1, 2026

COPD Assessment Test Score and Perioperative Risk in COPD

An observational study in COPD and Preoperative Risk Assessment, sponsored by Erzurum City Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Erzurum City Hospital · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey — 58 open to participants now, 68 under way, 7 of them phase 3. Pulmonary Disease, Chronic Obstructive · Turkey.

Planned enrollment
18th of 60
120 · median 77
Started
2025
with 26 others
Observational
60 of 248
19 open now
Primary completion
2027-01
later than 55 of 67 live
Registered
214th of 248
by date

Among the 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey, this one is the 18th largest by planned enrollment of the 60 observational ones that give a count, is one of 27 that started in 2025, is one of 60 observational ones, reaches primary completion later than 55 of the 67 other live ones, and was the 214th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

58 of the 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey are open now. Recruiting first, the newest first:

52 more — sign in →

All 58 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey, or all of them as a file.
02

Study summary

The goal of this observational cohort study is to evaluate whether the COPD Assessment Test (CAT) score can predict the risk of perioperative respiratory complications in patients aged 40 to 70 years with diagnosed Chronic Obstructive Pulmonary Disease (COPD), undergoing elective surgical procedures lasting no longer than 150 minutes.

The main questions it aims to answer are:

  • Is there a statistically significant association between preoperative CAT scores and the incidence of intraoperative and early postoperative respiratory complications in COPD patients?
  • Can the CAT score be effectively used as a preoperative risk stratification tool to guide anesthetic and surgical decision-making?

Researchers will compare two patient groups based on CAT scores: those with CAT \<10 and those with CAT ≥10 to determine whether higher CAT scores are associated with an increased incidence of perioperative respiratory complications.

Participants will:

  • Complete the CAT questionnaire during the preoperative evaluation
  • Undergo elective surgery with an expected duration of ≤150 minutes
  • Be monitored intraoperatively for bronchospasm, oxygen desaturation, and ventilation difficulty
  • Be monitored postoperatively (within the first 72 hours) for hypoxemia, reintubation, bronchospasm episodes, postoperative pneumonia, intensive care unit (ICU) admission, and length of hospital stay
  • Have perioperative clinical data collected and analyzed for comparative outcomes between CAT score subgroups
Read the detailed description

Chronic Obstructive Pulmonary Disease (COPD) is a common chronic respiratory disease associated with increased perioperative morbidity and mortality. Surgical procedures in COPD patients often carry higher risks of respiratory complications, making anesthetic management more challenging. The COPD Assessment Test (CAT) is a simple and practical tool developed to assess symptom burden in COPD patients and is being increasingly integrated into clinical practice. While its utility in evaluating disease-related symptoms and quality of life is well documented, the role of CAT score in predicting perioperative respiratory complications remains unclear.

This prospective observational cohort study aims to evaluate whether the CAT score can be used to predict perioperative respiratory risk and support clinical decision-making for anesthesiology and surgical teams. Based on previous estimates, patients with high CAT scores appear to be at greater risk for complications. A total of 120 patients will be enrolled in the study, with 60 patients in each group. Patients will be categorized into two groups based on their CAT scores:

Group 1: CAT \<10 (Low symptom burden)

Group 2: CAT ≥10 (High symptom burden)

Patients aged 40-70 years with a diagnosis of stable COPD scheduled for elective surgery lasting no more than 150 minutes will be included. The relationship between CAT score and perioperative respiratory complications will be statistically analyzed.

In the preoperative period (within 24 hours before surgery), data will be collected on demographics (age, sex, BMI, smoking history), comorbidities, surgical type (e.g., thoracic, abdominal, urological), ASA physical status classification, and planned anesthesia technique (general or regional). Arterial blood gas (ABG) samples at rest will be obtained. Additionally, Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) stage, spirometry data (Forced Expiratory Volume in 1 Second (FEV1), Forced Vital Capacity (FVC), FEV1/FVC ratio), and CAT score will be recorded by a pulmonologist.

During the perioperative period, ABG samples will be taken prior to induction and preoxygenation. All patients will receive standardized general anesthesia with full monitoring (Electrocardiogram (ECG), Peripheral Capillary Oxygen Saturation (SpO2), non-invasive blood pressure, capnography). Preoxygenation will be performed for at least 2 minutes. Anesthesia induction protocol includes:

  • 1-2 mg IV midazolam (premedication)
  • 0.3-0.5 mg/kg IV lidocaine
  • 1.5-2.5 mg/kg IV propofol
  • 0.6-1.2 mg/kg IV rocuronium
  • 1-2 mcg/kg IV fentanyl

After sufficient muscle relaxation, endotracheal intubation will be performed. All patients will be ventilated using volume-controlled ventilation with ideal body weight-based settings: tidal volume 6-8 mL/kg, respiratory rate 10-14/min, Positive End-Expiratory Pressure (PEEP) 3-5 cmH₂O, I:E ratio 1:2, and target End-Tidal Carbon Dioxide (EtCO₂) of 35-45 mmHg. Volatile anesthetics (sevoflurane or desflurane) will be administered at a minimum of 1.3 Minimum Alveolar Concentration (MAC). Intraoperative respiratory events (bronchospasm, desaturation, ventilation difficulty) will be observed and documented. A second ABG sample will be collected 2 minutes after induction.

At the end of surgery, patients will receive 10-15 mg/kg IV paracetamol and 1-2 mg/kg IV tramadol for analgesia. Neuromuscular blockade will be reversed with 2 mg/kg IV sugammadex.

Postoperatively, ABG samples will be taken in the Post-Anesthesia Care Unit (PACU) and again at the 72nd hour. The following respiratory complications will be recorded within the first 72 hours:

  • Hypoxemia (SpO₂ \<92%)
  • Reintubation requirement
  • Bronchospasm episodes
  • Postoperative pneumonia
  • Intensive Care Unit (ICU) admission
  • Length of hospital stay (in days)

All data will be collected by anesthesiologists involved in the study.

The primary objective of this study is to evaluate whether the preoperative CAT score can predict postoperative respiratory complications in patients with COPD. The secondary objective is to determine whether patients with high CAT scores require more postoperative oxygen therapy. The tertiary (exploratory) objective is to assess whether patients with higher CAT scores need more extensive medical optimization before surgery and whether the CAT score can serve as a useful guide in preoperative planning.

03

Conditions studied

  • COPD
  • Preoperative Risk Assessment

Keywords

  • COPD Assessment Test
  • COPD
  • Postoperative Respiratory Complications
  • Preoperative Risk Assessment
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged between 40 and 70 years with a diagnosis of stable-stage COPD according to GOLD criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 40 and 70 years
  • Diagnosed with stable-stage (COPD) according to GOLD criteria
  • Scheduled for elective surgical intervention
  • Classified as ASA Physical Status II or III according to the (ASA)
  • Planned for postoperative follow-up and eligible for at least 72 hours of observation
  • Undergoing surgery with an expected duration of at least 150 minutes
  • Willing to participate voluntarily in the study

Exclusion criteria

Exclusion Criteria:

  • Patients younger than 40 years or older than 70 years
  • History of exacerbation within the past 4 weeks
  • Presence of severe cardiac failure (EF \<30%), end-stage renal disease, or active
  • Neurological disorders or cognitive impairments
  • Requirement for invasive mechanical ventilation in the preoperative period
  • Altered consciousness or any condition preventing completion of forms before anesthesia
  • Undergoing surgery with an expected duration longer than 150 minutes
  • Unwillingness to participate in the study voluntarily
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Target follow-up
3 Days
Patient registry
Yes

Groups and cohorts

  • CAT <10 (Low symptom burden)

    Patients scheduled for elective surgery, diagnosed with COPD in a stable stage according to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria, and identified as having a low symptom burden (CAT \<10) based on preoperative CAT scoring

    Other: Arterial Blood Gas Analysis

  • CAT ≥10 (High symptom burden)

    Patients scheduled for elective surgery, diagnosed with COPD in a stable stage according to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria, and identified as having a high symptom burden (CAT ≥10) based on preoperative CAT scoring

    Other: Arterial Blood Gas Analysis

Interventions

  • OtherArterial Blood Gas Analysis

    Arterial blood gas analysis will be performed at predefined time points: at rest during the preoperative period, before induction and preoxygenation during the perioperative period, two minutes after induction but prior to intubation, within the first 30 minutes in the PACU during the postoperative period, and at the 72nd postoperative hour in the ward

06

What researchers measure

Primary outcomes

  1. Incidence of Postoperative Respiratory Complications Within 72 Hours

    Respiratory complications including hypoxemia (SpO₂ \< 90%), reintubation, bronchospasm, pneumonia, or ICU admission will be recorded during the first 72 hours after surgery. Each event will be assessed based on standardized clinical definitions. The outcome will be reported as the number of patients who experience at least one of the defined complications.

    Time frame: Within 72 hours postoperatively

Secondary outcomes

  1. Initiation of Postoperative Oxygen Therapy

    The requirement for supplemental oxygen within 72 hours after surgery will be recorded. Supplemental oxygen therapy will be initiated based on predefined clinical criteria such as SpO₂ \< 92% or signs of respiratory distress. The outcome will be reported as the number of patients who required oxygen therapy.

    Time frame: Within 72 hours postoperatively

  2. Duration of Postoperative Oxygen Therapy

    The total duration of postoperative oxygen therapy will be recorded for each patient from initiation to discontinuation, within the first 72 hours after surgery. The outcome will be reported as the number of hours per patient receiving oxygen therapy.

    Time frame: Within 72 hours postoperatively

  3. Maximum Oxygen Flow Rate Administered Postoperatively

    The highest flow rate of supplemental oxygen administered to each patient during the first 72 hours after surgery will be documented. The outcome will be expressed in liters per minute (L/min).

    Time frame: Within 72 hours postoperatively

Other outcomes

  1. Number of Patients Requiring Preoperative Medical Optimization

    The total number of COPD patients requiring preoperative medical optimization interventions prior to surgery will be recorded. The outcome will be expressed as the number of patients who received such interventions, including respiratory therapy adjustments, medication changes, or pulmonology consultations.

    Time frame: From preoperative assessment to day of surgery

  2. Types of Preoperative Interventions Performed

    A categorized record of preoperative medical interventions will be documented, including types such as bronchodilator adjustment, initiation of new medications, and pulmonology consultation. The outcome will be reported as the count of each intervention type (category-wise frequency).

    Time frame: From preoperative assessment to day of surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 16 months is below that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2025
First posted
Jul 28, 2025
StartActual
Aug 15, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07087626
Lead sponsor
Erzurum City Hospital
Responsible party
Mehmet Sercan Orbak (Anesthesiology Specialist (MD), Erzurum City Hospital) — Principal investigator
First posted
Jul 28, 2025
Start date
Aug 15, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

Mehmet S Orbak
Contact
sercanorbak@gmail.com
+ 90 (506) 288 35 34
Ahmet Ergün
Contact
draergn@gmail.com
+ 90 (543) 573 80 02
Mehmet S Orbak
principal investigator · Erzurum City Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion